- Home
- VERV
VERV
Verve Therapeutics Inc.
as 04-18-2025 12:45pm EST
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | $25.75 | AVG Volume (30 days): | 4.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.87 - $9.31 | Next Earning Date: | 05-07-2025 |
| Revenue: | $32,332,000 | Revenue Growth: | 174.98% |
| Revenue Growth (this year): | -23.81% | Revenue Growth (next year): | -46.54% |
Stock Insider Trading Activity of Verve Therapeutics Inc. (VERV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nickerson Joan | VERV | Chief Administrative Officer | Apr 1 '25 | Sell | $4.15 | 2,777 | $11,524.55 | 17,420 | |
| Dorval Allison | VERV | Chief Financial Officer | Apr 1 '25 | Sell | $4.15 | 3,350 | $13,902.50 | 13,280 | |
| Ashe Andrew D. | VERV | See Remarks | Apr 1 '25 | Sell | $4.15 | 2,681 | $11,126.15 | 348,828 | |
| Kathiresan Sekar | VERV | Chief Executive Officer | Apr 1 '25 | Sell | $4.15 | 9,822 | $40,761.30 | 346,686 | |
| Lister Troy | VERV | Chief Scientific Officer | Apr 1 '25 | Sell | $4.15 | 2,189 | $9,084.35 | 6,952 | |
| Politi Jason | VERV | Chief Technical Ops. Off. | Apr 1 '25 | Sell | $4.15 | 3,235 | $13,425.25 | 14,226 |
Latest Verve Therapeutics Inc. News
VERV Breaking Stock News: Dive into VERV Ticker-Specific Updates for Smart Investing
Motley Fool
16 hours ago
Why Verve Therapeutics Zoomed 40% Higher This Week
Zacks
3 days ago
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News
MT Newswires
4 days ago
Verve Therapeutics Shares Jump After Cantor Fitzgerald Upgrade
Motley Fool
4 days ago
Why Verve Therapeutics Is Skyrocketing Today
Zacks
4 days ago
VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study
MT Newswires
4 days ago
Cantor Fitzgerald Upgrades Verve Therapeutics to Overweight From Neutral
Simply Wall St.
4 days ago
Clover Health Investments Leads The Charge In These 3 Promising Penny Stocks
Pharmaceutical Technology
5 days ago
Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data
Compare VERV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VERV Verve Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.